Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 18, 2022

SELL
$65.85 - $96.21 $5.06 Million - $7.39 Million
-76,815 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$73.2 - $107.87 $5.62 Million - $8.29 Million
76,815 New
76,815 $6.31 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $986M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Castle Ark Alternatives, LLC Portfolio

Follow Castle Ark Alternatives, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Castle Ark Alternatives, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Castle Ark Alternatives, LLC with notifications on news.